Food and Drug Administration Efforts to Mitigate Contact Lens Discomfort

Denise Hampton1, Joffre Angelo Green, Marc Robboy

  • 1Division of Ear, Nose and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD.

Eye & Contact Lens
|December 13, 2016
PubMed

Insights

The U.S. Food and Drug Administration (FDA) reviews contact lenses and accessories, assessing nonclinical and clinical data for marketing approval. This process ensures safety and efficacy, incorporating wearer comfort factors and continuous improvement through collaboration.

Area of Science:

  • Ophthalmic device regulation
  • Medical device safety assessment

Background:

  • The U.S. Food and Drug Administration (FDA) regulates contact lenses and accessories.
  • Premarket review is crucial for ensuring the safety and efficacy of these medical devices.

Purpose of the Study:

  • To summarize the FDA's premarket review process for contact lenses and accessories.
  • To outline how attributes contributing to wearer comfort are assessed.
  • To describe mechanisms for ongoing assessment and improvement of FDA recommendations.

Main Methods:

  • Review of nonclinical and clinical data submitted in marketing applications.
  • Analysis of device attributes related to lens wearer comfort.
  • Examination of FDA's continuous improvement strategies and external collaborations.

Main Results:

  • The FDA's review encompasses comprehensive assessment of safety and performance data.
  • Factors influencing contact lens wearer comfort are integral to the evaluation.
  • The FDA employs ongoing evaluation and collaborative efforts to refine regulatory recommendations.

Conclusions:

  • The FDA's premarket review process for contact lenses is thorough, covering critical aspects of device performance and wearer well-being.
  • Continuous improvement and external collaboration enhance the regulatory framework for ophthalmic devices.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...